Paragraph 1
In the case of—
(a)
an active ingredient not described in the European Pharmacopoeia or in the pharmacopoeia of a member State; or
(b)
an active ingredient described in the European Pharmacopoeia or in the pharmacopoeia of a member State when prepared by a method liable to leave impurities not mentioned in the pharmacopoeial monograph and for which the monograph is inappropriate adequately to control its quality;
which is manufactured by a person other than the applicant, the latter may (subject to paragraph 2 below) arrange for the detailed description of the manufacturing method, quality control during manufacture and process validation to be supplied directly to the licensing authority by the manufacturer of the active ingredient.